Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cordlife GroupSGX:P8A +20.83%28 EV-to-FCF is 1.78 as of Aug. 14, 2026, which is 75% below its 10-year median of 7.25. GuruFocus rates SGX:P8A with a GF Score™ of 28/100 and a GF Value™ of S$0.17 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 101 Medical Diagnostics & Research companies, Cordlife Group ranks better than 94.06% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cordlife Group's Enterprise Value is S$-3.22 Mil.
Cordlife Group's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was S$-1.81 Mil. Therefore, Cordlife Group's EV-to-FCF for today is 1.78.
The historical rank and industry rank for Cordlife Group's EV-to-FCF or its related term are showing as below:
SGX:P8A'
s EV-to-FCF Range Over the Past 10 Years
Min: -93.67 Med: 7.25 Max: 84.34
Current: 3.91
During the past 13 years, the highest EV-to-FCF of Cordlife Group was 84.34. The lowest was -93.67. And the median was 7.25.
SGX:P8A's EV-to-FCF is ranked better than 94.06% of 101
companies
in the Medical Diagnostics & Research industry
Industry Median: 24.95
vs SGX:P8A: 3.91
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cordlife Group's PE Ratio (TTM) for today is calculated as:
Cordlife Group's share price for today is S$0.145.
Cordlife Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was S$-0.051.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cordlife Group EV-to-FCF Related Terms
Cordlife Group EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Cordlife Group's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Cordlife Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cordlife Group EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cordlife Group's EV-to-FCF falls into.
Cordlife Group's current Enterprise Value is S$-3.22 Mil.
Cordlife Group's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was S$-1.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cordlife Group (SGX:P8A) has a EV-to-FCF of 1.78 as of Aug. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cordlife Group and its competitors. This is 75% below median its historical median of 7.25. According to the industry distribution chart, Cordlife Group ranks #6 out of 101 companies in the Medical Diagnostics & Research industry, placing it in the top 5.9%.
Is Cordlife Group's EV-to-FCF too high?
Cordlife Group's current EV-to-FCF of 1.78 is 75% below median its 10-year median of 7.25. The Medical Diagnostics & Research industry median EV-to-FCF is 24.95. Cordlife Group's value of 1.78 is 92.9% below this industry median. Based on the distribution chart, Cordlife Group ranks #6 out of 101 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Cordlife Group has a GF Score™ of 28/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #6 out of 101 companies for EV-to-FCF. This places Cordlife Group in the top 6% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 24.95. Cordlife Group's value of 1.78 is 92.9% below this benchmark. While the company's 10-year median is 7.25 vs. the industry median of 24.95, Cordlife Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 24.95, based on 101 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cordlife Group's current EV-to-FCF of 1.78 is 92.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cordlife Group and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 24.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cordlife Group's current EV-to-FCF is 1.78, which is 75% below median its own 10-year median of 7.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (SGX:P8A) is currently considered Modestly Undervalued. The stock's GF Value™ is S$0.17, compared to a current price of S$0.15 — trading 14.7% below its estimated fair value. The current EV-to-FCF is 1.78, which is 75% below median its 10-year median of 7.25 and 92.9% below the Medical Diagnostics & Research industry median of 24.95. Cordlife Group's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Cordlife Group (SGX:P8A), the current EV-to-FCF is 1.78 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cordlife Group (SGX:P8A) Overvalued in 2026?
Based on GuruFocus' analysis, Cordlife Group stock appears to be undervalued.
The current stock price of S$0.15 is trading 14.7% below its estimated GF Value™ of S$0.17.
GuruFocus considers Cordlife Group to be Modestly Undervalued.
Key valuation signals for SGX:P8A:
EV-to-FCF: 1.78 (75% below median its 10-year median of 7.25)
GF Value™: S$0.17 vs. price of S$0.15 (14.7% below fair value)
Industry Position: 92.9% below the Medical Diagnostics & Research median (#6 of 101)
No single metric tells the full story. See the SGX:P8A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
28GF Score
Get the complete analysis for SGX:P8A
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:P8A has been successfully added to your 
